Clinical Trials Logo

Clinical Trial Summary

The primary objective of this study is to investigate whether eradication treatment of Helicobacter pylori followed by therapy with esomeprazole for a total of 8 weeks extends the time to relapse in patients with gastroesophageal reflux disease (GERD).

A relapse is defined by two consecutive symptom scores of the Eraflux questionnaire within 14 days that are equal or above the critical value of 25.

The secondary objectives are

1. To compare the time to relapse in the two H. pylori positive study groups with the H. pylori negative control group

2. To compare the pattern of inflammation and atrophy in the two H. pylori positive treatment groups with the naturally H. pylori negative control group at relapse.

3. All the above objectives analyzed for the efficacy subset that is the per-protocol patients broken down by effective H. pylori-eradication.

Secondary endpoints will be analyzed by the following parameters and their interactions:

1. Treatment : Eradicated, Non-eradicated, Hp-negative control

2. Esophagitis at study start: grades 0, A/B and C/D

3. Gender

4. Alcohol intake

5. NSAID/ASA intake (for histological results)

- Trial with medicinal product


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00574925
Study type Interventional
Source University of Zurich
Contact
Status Completed
Phase Phase 4
Start date November 2003
Completion date October 2007

See also
  Status Clinical Trial Phase
Completed NCT03561883 - Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs) Phase 3
Completed NCT02555852 - Proton Pump Inhibitors and Risk of Community-acquired Pneumonia N/A
Completed NCT01406210 - RESULT (REflux Surgery in Lung Transplantation) Preliminary Study Protocol N/A
Terminated NCT01327963 - Retrospective TIF Study for Treatment of Gastroesophageal Reflux Disease (GERD). The RetroTIF Study N/A
Completed NCT01570842 - Anthropometry in Gastroesophageal Reflux Disease and Esophageal Injury N/A
Completed NCT02141711 - TAK-438 - Safety, Blood Levels & Effects of Repeated Doses Phase 1
Terminated NCT00587275 - Safety and Efficacy of AST-120 in Patients With GERD Who Continue to be Symptomatic on a Standard Dose of PPI Phase 2
Completed NCT00228527 - Esomeprazole for Treatment of GERD in Pediatric Patients Phase 4
Completed NCT00261300 - Long-term Pantoprazole Trial in Patients With Symptoms of Chronic Acid Peptic Complaints (BY1023/VMG-708) Phase 3
Recruiting NCT04506593 - Indiana University Gastrointestinal Motility Diagnosis Registry
Completed NCT00795093 - Partial Response to Proton Pump Inhibitors (PPI) Treatment: The Cost to Society and the Burden to the Patient - a Study in the US N/A
Completed NCT00394472 - Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients Phase 2
Terminated NCT02749071 - An Investigation of the EndoStim® Lower Esophageal Sphincter (LES) Stimulation System for the Treatment of Reflux N/A
Recruiting NCT01129713 - Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in GERD Patients With Severe EE. Phase 1/Phase 2
Completed NCT00734747 - Safety and Efficacy the Medigus SRS Endoscopic Stapling System in Gastroesophageal Reflux Disease (GERD) Phase 3
Completed NCT00312806 - Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients (BY1023/M3-341) Phase 3
Not yet recruiting NCT05579587 - Transoral Incisionless Fundoplication (TIF) for Laryngopharyngeal Reflux (LPR) Patients
Recruiting NCT02366169 - Medigus Ultrasonic Surgical Endostapler (MUSE) Registry N/A
Completed NCT01374074 - Racial Disparity in Barrett's Esophagus N/A
Terminated NCT00857597 - Endoscopic Fundoplication Versus Proton Pump Inhibitors for GERD Treatment Phase 3